BACKGROUND: There is an unmet need for a modular artificial pancreas (AP) system for clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, and tested the interoperable artificial pancreas system (iAPS) smartphone app that can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, and decision-making algorithms while running on an unlocked smartphone. METHODS: After algorithm verification, hazard and mitigation analysis, and complete system verification of iAPS, six adults with type 1 diabetes completed 1 week of sensor-augmented pump (SAP) use followed by 48 h of AP use with the iAPS, a Dexcom G5 CGM, and either a Tandem or Insulet insulin pump in an investigational device exemption study. The AP system was challenged by participants performing extensive walking without exercise announcement to the controller, multiple large meals eaten out at restaurants, two overnight periods, and multiple intentional connectivity interruptions. RESULTS: Even with these intentional challenges, comparison of the SAP phase with the AP study showed a trend toward improved time in target glucose range 70-180 mg/dL (78.8% vs. 83.1%; P = 0.31), and a statistically significant reduction in time below 70 mg/dL (6.1% vs. 2.2%; P = 0.03). The iAPS system performed reliably and showed robust connectivity with the peripheral devices (99.8% time connected to CGM and 94.3% time in closed loop) while requiring limited user intervention. CONCLUSIONS: The iAPS system was safe and effective in regulating glucose levels under challenging conditions and is suitable for use in unconstrained environments.
BACKGROUND: There is an unmet need for a modular artificial pancreas (AP) system for clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, and tested the interoperable artificial pancreas system (iAPS) smartphone app that can interface wirelessly with leading continuous glucose monitors (CGM), insulin pump devices, and decision-making algorithms while running on an unlocked smartphone. METHODS: After algorithm verification, hazard and mitigation analysis, and complete system verification of iAPS, six adults with type 1 diabetes completed 1 week of sensor-augmented pump (SAP) use followed by 48 h of AP use with the iAPS, a Dexcom G5 CGM, and either a Tandem or Insulet insulin pump in an investigational device exemption study. The AP system was challenged by participants performing extensive walking without exercise announcement to the controller, multiple large meals eaten out at restaurants, two overnight periods, and multiple intentional connectivity interruptions. RESULTS: Even with these intentional challenges, comparison of the SAP phase with the AP study showed a trend toward improved time in target glucose range 70-180 mg/dL (78.8% vs. 83.1%; P = 0.31), and a statistically significant reduction in time below 70 mg/dL (6.1% vs. 2.2%; P = 0.03). The iAPS system performed reliably and showed robust connectivity with the peripheral devices (99.8% time connected to CGM and 94.3% time in closed loop) while requiring limited user intervention. CONCLUSIONS: The iAPS system was safe and effective in regulating glucose levels under challenging conditions and is suitable for use in unconstrained environments.
Entities:
Keywords:
Artificial pancreas; Mobile apps; Type 1 diabetes; mHealth.
Authors: Eyal Dassau; Jordan E Pinsker; Yogish C Kudva; Sue A Brown; Ravi Gondhalekar; Chiara Dalla Man; Steve Patek; Michele Schiavon; Vikash Dadlani; Isuru Dasanayake; Mei Mei Church; Rickey E Carter; Wendy C Bevier; Lauren M Huyett; Jonathan Hughes; Stacey Anderson; Dayu Lv; Elaine Schertz; Emma Emory; Shelly K McCrady-Spitzer; Tyler Jean; Paige K Bradley; Ling Hinshaw; Alejandro J Laguna Sanz; Ananda Basu; Boris Kovatchev; Claudio Cobelli; Francis J Doyle Journal: Diabetes Care Date: 2017-10-13 Impact factor: 19.112
Authors: Daniel A Finan; Eyal Dassau; Marc D Breton; Stephen D Patek; Thomas W McCann; Boris P Kovatchev; Francis J Doyle; Brian L Levy; Ramakrishna Venugopalan Journal: J Diabetes Sci Technol Date: 2015-06-30
Authors: Lauren M Huyett; Trang T Ly; Gregory P Forlenza; Suzette Reuschel-DiVirgilio; Laurel H Messer; R Paul Wadwa; Ravi Gondhalekar; Francis J Doyle; Jordan E Pinsker; David M Maahs; Bruce A Buckingham; Eyal Dassau Journal: Diabetes Technol Ther Date: 2017-05-01 Impact factor: 6.118
Authors: Bruce A Buckingham; Mark P Christiansen; Gregory P Forlenza; R Paul Wadwa; Thomas A Peyser; Joon Bok Lee; Jason O'Connor; Eyal Dassau; Lauren M Huyett; Jennifer E Layne; Trang T Ly Journal: Diabetes Technol Ther Date: 2018-08-02 Impact factor: 6.118
Authors: Boris Kovatchev; Stacey M Anderson; Dan Raghinaru; Yogish C Kudva; Lori M Laffel; Carol Levy; Jordan E Pinsker; R Paul Wadwa; Bruce Buckingham; Francis J Doyle; Sue A Brown; Mei Mei Church; Vikash Dadlani; Eyal Dassau; Laya Ekhlaspour; Gregory P Forlenza; Elvira Isganaitis; David W Lam; John Lum; Roy W Beck Journal: Diabetes Care Date: 2020-01-14 Impact factor: 19.112
Authors: Basak Ozaslan; Carol J Levy; Yogish C Kudva; Jordan E Pinsker; Grenye O'Malley; Ravinder Jeet Kaur; Kristin Castorino; Camilla Levister; Mari Charisse Trinidad; Donna Desjardins; Mei Mei Church; Mitchell Plesser; Shelly McCrady-Spitzer; Selassie Ogyaadu; Kristen Nelson; Corey Reid; Sunil Deshpande; Walter K Kremers; Francis J Doyle; Barak Rosenn; Eyal Dassau Journal: Diabetes Technol Ther Date: 2022-04-26 Impact factor: 7.337
Authors: Marzia Cescon; Divya Choudhary; Jordan E Pinsker; Vikash Dadlani; Mei Mei Church; Yogish C Kudva; Francis J Doyle Iii; Eyal Dassau Journal: Comput Biol Med Date: 2021-07-12 Impact factor: 6.698
Authors: Eleonora M Aiello; Sunil Deshpande; Basak Ozaslan; Kelilah L Wolkowicz; Eyal Dassau; Jordan E Pinsker; Francis J Doyle Journal: Curr Opin Biomed Eng Date: 2021-06-18